{"sequenceId":"845361905918","id":"34207100951","language":"English","title":"Amicus Therapeutics, Inc. (FOLD) Expected to Announce Earnings of -$0.33 Per Share","content":"Equities analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings of ($0.33) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. Amicus Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The business is scheduled to report its next earnings results on Monday, August 6th.  On average, analysts expect that Amicus Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.99). For the next fiscal year, analysts forecast that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.42) to ($0.47). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Amicus Therapeutics. Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. The firm had revenue of $16.70 million during the quarter, compared to analyst estimates of $16.78 million. Several brokerages have issued reports on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 10th. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Cowen reaffirmed a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. Finally, Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.06.  FOLD stock traded down $0.39 during mid-day trading on Friday, hitting $16.51. 1,624,860 shares of the stock were exchanged, compared to its average volume of 2,979,463. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32. Amicus Therapeutics has a 12 month low of $8.04 and a 12 month high of $17.40. The firm has a market cap of $3.21 billion, a P/E ratio of -5.65 and a beta of 1.48.   In other news, SVP Daphne Quimi sold 8,750 shares of Amicus Therapeutics stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $15.00, for a total value of $131,250.00. Following the transaction, the senior vice president now owns 73,082 shares in the company, valued at $1,096,230. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc acquired 335,827 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was bought at an average price of $13.56 per share, for a total transaction of $4,553,814.12. The disclosure for this purchase can be found here. In the last quarter, insiders sold 128,750 shares of company stock worth $1,921,300. Company insiders own 2.90% of the company’s stock.   Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Palisade Capital Management LLC NJ purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $211,000. Xact Kapitalforvaltning AB purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $219,000. Rockefeller Financial Services Inc. purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $276,000. Rockefeller Capital Management L.P. purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $288,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $383,000.   About Amicus Therapeutics  Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"Equities analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings of ($0.33) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. Amicus Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The business is scheduled to report its next earnings results on Monday, August 6th.  On average, analysts expect that Amicus Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.99). For the next fiscal year, analysts forecast that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.42) to ($0.47). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Amicus Therapeutics. Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. The firm had revenue of $16.70 million during the quarter, compared to analyst estimates of $16.78 million. Several brokerages have issued reports on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 10th. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Cowen reaffirmed a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. Finally, Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.06.  FOLD stock traded down $0.39 during mid-day trading on Friday, hitting $16.51. 1,624,860 shares of the stock were exchanged, compared to its average volume of 2,979,463. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32. Amicus Therapeutics has a 12 month low of $8.04 and a 12 month high of $17.40. The firm has a market cap of $3.21 billion, a P/E ratio of -5.65 and a beta of 1.48.   In other news, SVP Daphne Quimi sold 8,750 shares of Amicus Therapeutics stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $15.00, for a total value of $131,250.00. Following the transaction, the senior vice president now owns 73,082 shares in the company, valued at $1,096,230. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc acquired 335,827 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was bought at an average price of $13.56 per share, for a total transaction of $4,553,814.12. The disclosure for this purchase can be found here. In the last quarter, insiders sold 128,750 shares of company stock worth $1,921,300. Company insiders own 2.90% of the company’s stock.   Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Palisade Capital Management LLC NJ purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $211,000. Xact Kapitalforvaltning AB purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $219,000. Rockefeller Financial Services Inc. purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $276,000. Rockefeller Capital Management L.P. purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $288,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Amicus Therapeutics in the first quarter worth about $383,000.   About Amicus Therapeutics  Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-02T21:20:38Z","harvestDate":"2018-06-02T21:21:55Z","estimatedPublishedDate":"2018-06-02T21:20:38Z","url":"http://ct.moreover.com/?a=34207100951&p=1u0&v=1&x=1WsioqpcFTPHmPOOG5SN3w","originalUrl":"https://www.thestockobserver.com/2018/06/02/amicus-therapeutics-inc-fold-expected-to-announce-earnings-of-0-33-per-share.html","outboundUrls":["https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=FOLD","https://www.marketbeat.com/stocks/NASDAQ/FOLD/","http://www.sec.gov/Archives/edgar/data/1178879/000120919118018938/xslF345X03/doc4.xml","http://www.sec.gov/Archives/edgar/data/1164426/000101297518000267/xslF345X03/edgar.xml","https://www.zacks.com/registration/pfp/?ALERT=zrmodule&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=FOLD"],"wordCount":"735","dataFormat":"text","duplicateGroupId":"34200376041","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Finance latest","group":"Finance"},{"name":"Earnings news","group":"Finance"},{"name":"Stockwatch","group":"Finance"}],"companies":[{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"BER","isin":"US03152W1099","titleCount":1,"contentCount":21,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"FOLD","exchange":"NAS","isin":"US03152W1099","titleCount":1,"contentCount":21,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"FRA","isin":"US03152W1099","titleCount":1,"contentCount":21,"primary":true},{"name":"Amicus Therapeutics Inc","symbol":"AM6","exchange":"STU","isin":"US03152W1099","titleCount":1,"contentCount":21,"primary":true},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"FRA","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TOC","exchange":"MUN","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"NYS","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI","exchange":"TSE","isin":"CA8849031056","titleCount":0,"contentCount":1,"primary":false},{"name":"Thomson Reuters Corp","symbol":"TRI.PR.B","exchange":"TSE","isin":"CA8849033037","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Brian Himes","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Stock Observer.com","homeUrl":"https://www.thestockobserver.com","category":"Trade","editorialRank":"3","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"627334761","name":"Stock Observer.com","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials"],"genre":"General"}},"es_id":86989965}